Patient characteristics and parameters assessed |
Standard therapy |
Standard therapy+ PTX |
p-value |
Age |
28.8±7.7 |
30.7±7.1 |
0.29 |
NYHA FC |
3.1±0.6 |
3.4±0.6 |
0.032 |
Pulse rate/min |
100.4±16.3 |
102.3±21.4 |
0.68 |
DBP (mmHg) |
74.2±10.2 |
76.0±14.3 |
0.53 |
SBP (mmHg) |
110.1±16.4 |
115.2±20.5 |
0.26 |
LVESD (mm) |
48.5±6.0 |
49.2±6.5 |
0.57 |
LVEDD (mm) |
56.2±5.8 |
57.2±6.1 |
0.38 |
LVEF (%) |
29.9±8.0 |
29.1±9.4 |
0.65 |
Table 1:
Patient characteristics and parameters assessed |
Standard therapy |
Standard therapy+ PTX |
p-value |
Deceased |
1 |
4 |
0.36 |
NYHA FC |
1.5±0.7 |
1.5±0.7 |
0.75 |
Pulse rate/min |
81.5±13.5 |
87.8±19.3 |
0.19 |
DBP (mmHg) |
70.8±11.5 |
71.8±13.2 |
0.72 |
SBP (mmHg) |
107.5±13.8 |
110.0±17.1 |
0.52 |
LVESD (mm) |
39.7±8.0 |
40.5±8.2 |
0.65 |
LVEDD (mm) |
50.1±8.2 |
52.6±7.2 |
0.18 |
LVEF (%) |
42.3±10.5 |
46.8±11.4 |
0.11 |
Table 2: Results of the studies at 6-months
Tables at a glance